Phase 3
Completed N=2,222
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Urinary Tract Infections · Cystitis
Source: ClinicalTrials.gov NCT05584657 ↗
Enrolled (actual)
2,222
Serious AEs
0.2%
Results posted
Nov 2024
Primary outcomePrimary: Overall Success — 318; 260 Participants
◆ Published Evidence
Emerging
8citations · ~8 / year
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Summary
Study 310 is a clinical study which compares the effectiveness of oral sulopenem versus oral amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection.
Linked Publications
-
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Success |
318; 260 | — |
| PRIMARY Overall Success Susceptible Population |
296; 243 | — |
| SECONDARY Clinical Success Modified Intent-to-treat Population |
851; 849 | — |
| SECONDARY Clinical Success |
397; 358 | — |
| SECONDARY Clinical Success Susceptible Population |
371; 339 | — |
| SECONDARY Microbiologic Success |
390; 315 | — |
| SECONDARY Microbiologic Success Susceptible Population |
361; 295 | — |
Eligibility Criteria
Inclusion Criteria
- Female patients ≥18 years of age with ≥24 hours and ≤96 hours of urinary symptoms attributable to a UTI
- Two of the following signs and symptoms of uUTI: urinary frequency, urinary urgency, pain or burning on micturition, suprapubic pain.
- A mid-stream urine specimen with evidence of pyuria as defined by either a machine-read dipstick positive for leukocyte esterase OR at least 10 white blood cells per cubic millimeter on microscopic analysis of unspun urine OR white blood cell count ≥10 cells/high-powered field (HPF) in the sediment of a spun urine
Exclusion Criteria
- Presence of signs and symptoms suggestive of acute pyelonephritis defined as: fever (temperature > 38° Celsius), chills, costovertebral angle tenderness, flank pain, nausea, and/or vomiting
- Receipt of antibacterial drug therapy potentially effective as treatment of uUTI within the prior 7 days
- Concurrent use of non-study treatments that would have a potential effect on outcome evaluations in patients with uUTI, including analgesics (e.g., non-steroidal anti-inflammatory drugs, aspirin, paracetamol etc.), phenazopyridine, and cranberry products.
- Any anatomical abnormality of the urinary tract, including surgically modified urinary tract anatomy, and obstructive uropathy due to nephrolithiasis, stricture, tumor, or fibrosis
- Ongoing urinary retention
- Neurogenic bladder
- Current resident of a long-term care facility
- Instrumentation of urinary tract in the previous 30 days
- An indwelling urinary catheter, ureteral stent or other foreign material in the urinary tract
- Any history of trauma to the pelvis or urinary tract
- Receiving hemodialysis, hemofiltration, peritoneal dialysis, or had a renal transplant
- History of allergy or hypersensitivity to carbapenems, β-lactams or probenecid, as formulated with their excipients
Data sourced from ClinicalTrials.gov (NCT05584657) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.